این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
یکشنبه 30 آذر 1404
Journal of Research in Medical Sciences
، جلد ۲۸، شماره ۳۱، صفحات ۲۰۲۳-۲۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Efficacy of metformin adjunctive therapy as the treatment for non?diabetic patients with advanced non small cell lung cancer A Systematic review and Meta analysis
چکیده انگلیسی مقاله
Background: Currently, the anticancer effects of metformin on different types of lung cancer have been frequently studied. However, the elationship between metformin and prognosis in nondiabetic patients with lung cancer remains controversial. To systematically evaluate the efficacy of metformin adjunctive therapy as the treatment for nondiabetic patients with advanced non?small cell lung cancer (NSCLC) to provide an evidence?based reference for clinical medication. Materials and Methods: The literatures related to Phase II or III randomized controlled trials (RCTs) of metformin adjunctive therapy in nondiabetic patients with advanced NSCLC, including EMBASE, PubMed, the Cochrane Library, and Scopus database, were retrieved by computer, and the search time ranged from January 2017 to August 2022. The risk of bias assessment tool recommended by Cochrane Systematic Evaluator Manual 5.1.0 was used to evaluate the quality of the RCTs included. Rev Man 5.3 software and STATA15.0 were used for meta?analysis. Results: A total of 8 studies were included (925 patients). Meta?analysis results showed that there were no significant differences inrogression?free survival (PFS) (hazard ratio [HR] = 0.95, 95% confidence interval [CI]: 0.66–1.36, P = 0.77), overall survival (OS) (HR = 0.89, 95% CI: 0.61–1.30, P = 0.55, n =7), objective response rate (ORR) (odds ratio [OR] = 1.37, 95% CI: 0.76–2.46, P = 0.30), and 1?year PFS rate (OR = 0.87, 95% CI: 0.39–1.94, P = 0.73, n = 3). Sensitivity analysis showed that PFS and OS indexes were stable. Conclusion: Metformin adjunctive therapy can improve the DCR of nondiabetic patients with advanced NSCLC. In addition, the patients cannot obtain a prolonged PFS, OS, 1?year PFS rate, and higher ORR rate.
کلیدواژههای انگلیسی مقاله
Meta?analysis, metformin, non?small cell lung cancer, systematic review
نویسندگان مقاله
| Xueyu Duan
| Binbin Liao
| Xiaobo Liu
| Ruixiang Chen
نشانی اینترنتی
http://jrms.mui.ac.ir/index.php/jrms/article/view/11450
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
Review Article
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات